Risk of Hysterectomy at Time of Myomectomy

The Risk of Hysterectomy at Time of Myomectomy at Ain Shams University Hospital: A Retrospective Cohort Study.

Uterine fibroids are the commonest tumor affecting the female reproductive tract and many instances they are asymptomatic but in some women there does appear to be an association with heavy menstrual blood loss and possibly subfertility. Classically, treatment has been surgical with hysterectomy the most common approach for women who have completed their fertility and myomectomy for those who wish to conceive. The surgery can be carried out laparoscopically, vaginally and abdominally. The aim of this study is to evaluate the risk of hysterectomy at the time of myomectomy, and the associated 30-day postoperative morbidity.

Study Overview

• Status: Completed
• Conditions: Hysterectomy; Fibroid Uterus; Myomectomy

Detailed Description

Uterine fibroids are the most common benign tumors in reproductive age women affecting up to 80% of women (Havryliuk et al., 2017; Fortin et al., 2018). The cumulative incidence of uterine fibroids by age 50 years can be as high as 70% in white women and more than 80% in black women (Laughlin-Tommaso., 2016).

In many women, myomas may be asymptomatic and are diagnosed incidentally on clinical examination or imaging. 20% to 50% of patients with myoma experience symptoms, such as pelvic pain, heavy menstrual bleeding (HMB), iron deficiency anemia, pressure symptoms, or infertility (Bosteels et al., 2018).Treatment options for uterine fibroids include expectant, medical, or surgical management or by interventional radiology. The ideal treatment should be tailored according to the size, and location of the fibroid, in addition to the patient's age, symptoms, desire for future fertility and physician experience (Evangelisti et al., 2022).

Medical treatment is the hormonal therapy, which can cause shrinkage in the size of myoma, and relieve symptoms but it does not eliminate the disease and that's why if it is effective, it should be used chronically (Evangelisti et al., 2022).

Treatment by interventional radiology could provide an alternative, such as uterine artery embolization (UAE), high-intensity focused ultrasound, or transcervical radiofrequency ablation (Hartmann et al., 2017). In Uterine artery embolization, embolic agents are injected into the arteries that supply the uterus to cut off blood flow to fibroids, causing them to shrink and die that will relieve the symptoms. (Spies JB., 2016) Complications may happen if the blood supply to the ovaries or other organs is reduced. Radiofrequency ablation destroys uterine fibroids and shrinks the blood vessels that feed them, it can be performed through laparoscopy or through transvaginal or transcervical approach(Bradely et al .,2019) In recent years, it has been reported that UAE enables myomectomy with only minimal blood loss. Thereby devascularizing the leiomyoma and allowing for bloodless dissection (McLucas and Voorhees, 2015). This combination of two established procedures is intended to preserve the uterus in women with large and multiple fibroids who are at risk for blood loss including subsequent transfusions as well as conversion to hysterectomy.

Among uterus-preserving therapeutic options, myomectomy is the most widely performed intervention. Yet, for patients with myomas that are large, numerous, or unfavorably located, myomectomy is associated with an elevated risk for intraoperative bleeding and hysterectomy because of tumor-related neovascularization and anatomy distortion (Lethaby et al., 2017; Vargas MV et al., 2017).

Hysterectomy is the most performed surgical treatment for myoma-related symptoms, whereas myomas are also the leading indication for surgery in women of the reproductive age (Stewart et al., 2016; Laughlin-Tommaso et al., 2020). It is associated with significant morbidity, mortality, and economic burden on the health care system (Clark-Pearson and Geller.,2 013).

Although hysterectomy provides definitive treatment for symptomatic women, it may not be a viable option for young women and those who desire fertility preservation, alternatives must be considered. Uterine preservation options are becoming increasingly important. The most common non-pharmacologic solution for women who desire future childbearing is a myomectomy (Laughlin-Tommaso., 2016).

Although quality of life (QoL) after myomectomy is adequately studied and indicates a significant improvement after both short- and long-term follow-up (Hartmann et., al 2017; Daniels et al., 2022).

Several studies that have surveyed women on their attitudes about hysterectomy versus uterine sparing procedures demonstrated that a significant portion of patients wish to preserve the uterus for personal identity, culture, and religious considerations. Uterine preservation has also been shown to have better outcomes regarding self-esteem, sexuality and body image compared to hysterectomy (Wilson, 2018).

The hypothesis of this study is that analysis of the data of the patients with myomas that required hysterectomy at time of myomectomy could help in counselling of patients regarding the risks during surgery especially for young patient desire fertility.

• Study Type: Observational
• Enrollment (Actual): 293

Contacts and Locations

Study Locations

• Egypt
  • Cairo, Egypt, 11591
    • Faculty of Medicine, Ain Shams University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Women who were planned to undergo abdominal myomectomy in the past 4 years

Description

Inclusion Criteria:

• Women planned for abdominal myomectomy in the previous 4 years.
• Availability of complete medical records for pre-, intra- and post-operative data.

Exclusion Criteria:

• Missing or lacking information in the patients records like preoperative assessment of the fibroid uterus.
• Absence of operative notes and relevant data in the medical files.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Patient who were planned for abdomoinal myomectomy; A retrospective study on women who were candidates for abdominal myomectomy in the previous 4 years

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence of hysterectomy at time of myomectomy.	Jan 2020- Dec 2024

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Characteristics of the Myomas who required hysterectomy	number, site, size, Figo staging	Jan 2020- Dec 2024
Intraoperative complications	Anesthesia complication, organ injury, blood transfusion.	Jan 2020- Dec 2024
Postoperative complications	Anemia, hemorrhage, fever, wound infection, wound hematoma	Jan 2020- Dec 2024
Duration of hospital stay	in days	Jan 2020- Dec 2024
Reoperation	within 5 days of surgery	Jan 2020- Dec 2024
Readmission after discharge from the hospital	within 14 days	Jan 2020- Dec 2024

Collaborators and Investigators

• Sponsor: Ain Shams University

Study record dates

Study Major Dates

• Study Start (Actual): December 15, 2024
• Primary Completion (Actual): October 15, 2025
• Study Completion (Actual): October 15, 2025

Study Registration Dates

• First Submitted: January 17, 2026
• First Submitted That Met QC Criteria: January 17, 2026
• First Posted (Actual): January 26, 2026

Study Record Updates

• Last Update Posted (Actual): January 30, 2026
• Last Update Submitted That Met QC Criteria: January 28, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: hysterectomy; myomectomy; fibroid uterus
• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Histologic Type; Neoplasms, Connective and Soft Tissue; Neoplasms, Muscle Tissue; Leiomyoma
• Other Study ID Numbers: FMASU MS 778/2024

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No